Related Experiment Videos
An advanced chronic heart failure day care service: a 5 year single-center experience
Dov Freimark1, Michael Arad, Shlomi Matetzky
1Heart Failure Service, Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel.
Insights
A specialized heart failure day care service safely reduced hospitalizations and mortality in advanced chronic heart failure (CHF) patients. This supportive model, including multidrug intravenous therapy and patient education, shows significant benefits for managing complex CHF cases.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Pharmacy
Background:
- Chronic heart failure (CHF) is a major cause of hospitalizations and mortality.
- Advanced CHF presents significant management challenges and a poor prognosis.
Purpose of the Study:
- To evaluate the 5-year experience of a single-center CHF day care service.
- To identify cardiovascular and non-cardiovascular events in patients treated at the service.
- To assess the safety and efficacy of treatments administered in the CHF day care setting.
Main Methods:
- Retrospective study of 190 advanced CHF patients (NYHA class III-IV) treated between 2000-2005.
- Patients received biweekly 6-hour visits with intravenous therapies including diuretics, dobutamine, dopamine, iron/blood, and nitroprusside.
- Follow-up data for at least 1 year was obtained for 83% of patients.
Main Results:
- The study treated 190 advanced CHF patients with a mean age of 65 years and LVEF of 25%.
- Common treatments included intravenous diuretics (91%), dobutamine (87%), and iron/blood (47%).
- Mortality was 29.3% (23% due to CHF exacerbation), with a low rehospitalization rate of 0.68/patient/year, primarily for CHF exacerbation (16.5%).
Conclusions:
- A supportive CHF day care service is safe and beneficial for advanced CHF patients.
- Multidrug intravenous treatment, monitoring, education, and psychological support can reduce morbidity.
- This model may contribute to lower-than-expected mortality and hospitalization rates in advanced CHF.
Background:
Chronic heart failure is associated with excessive hospitalizations and poor prognosis.
Objectives:
To summarize the 5 year experience of a single-center CHF day care service, detect the cardiovascular and non-cardiovascular events, and evaluate the safety of the treatments provided.
Methods:
We retrospectively studied all patients admitted to the CHF day care service of the Sheba Medical Center between September 2000 and September 2005.
Results:
Advanced (New York Heart Association class III-IV) CHF patients (n = 190), mean age 65 +/- 12 years and left ventricular ejection fraction 25 +/- 11%, were treated for 6 hourly biweekly visits; 77% had ischemic and 23% had nonischemic cardiomyopathy. Treatment included: intravenous diuretic combinations (91%), intermittent low dose (< or = 5 microg/kg/min) dobutamine (87%), low dose (< or = 3 microg/kg/min) dopamine (38%), intravenous iron preparation and/or blood (47%), and intravenous nitropruside (36%). Follow-up of at least 1 year from initiation of therapy was completed in 158 of 190 patients (83%). Forty-six (29.3%) died: 23% due to CHF exacerbation, 5.7% from infection, 4.4% from sudden cardiac death, 3.8% from malignancy, 2.5% from malignant arrhythmias, 1.9% from renal failure, 1.3% from stroke, and 0.6% from myocardial infarction. There were only 0.68 rehospitalizations/patient/year; the most frequent cause being CHF exacerbation (16.5%).
Conclusions:
Our study demonstrates the safety and potential benefits of a supportive day care service for advanced CHF patients. Multidrug intravenous treatment, accompanied by monitoring of electrolytes, hemoglobin and cardiac rhythm, along with education and psychological support, appear to reduce morbidity in advanced CHF patients and may have contributed to the lower than expected mortality/ hospitalization rate.
Related Concept Videos
Continuing Care
Heart Failure VII: Nursing Interventions
Heart Failure V: Medical Management
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure III: Clinical Manifestations